Uptravi 400 mcg Film-Coated Tablets, containing the active substance Selexipag, is a specialized oral treatment developed to combat pulmonary arterial hypertension (PAH). Manufactured by Janssen Pharmaceuticals, Uptravi targets a crucial pathway in PAH management, the prostacyclin receptor, offering patients a modern, effective alternative to traditional therapies.
Selexipag, as a selective prostacyclin IP receptor agonist, plays a dual role: it promotes vasodilation (relaxation of blood vessels) while simultaneously inhibiting abnormal proliferation of smooth muscle cells in the pulmonary arteries. This dual action not only alleviates symptoms but also slows the progression of pulmonary arterial hypertension, a rare and life-threatening condition characterized by high blood pressure in the arteries of the lungs.
Key Benefits of Uptravi 400 mcg:
- Disease Progression Delay: Clinically shown to significantly reduce the risk of PAH-related hospitalizations and disease progression.
- Exercise Capacity Improvement: Enhances physical activity levels, enabling patients to regain control over their daily lives.
- Convenient Oral Therapy: Offers the prostacyclin pathway’s benefits without the complexity of intravenous or inhaled treatments.
- Personalized Dosage: Titration process allows physicians to adjust the dose according to patient tolerance, optimizing effectiveness and minimizing side effects.
Dosage & Administration:
- Initial Dosage: Typically starts at a low dose and is gradually increased based on individual tolerance.
- Recommended Intake: 400 mcg twice daily with food to reduce potential gastrointestinal discomfort.
- Maximum Dose: Determined by patient response, often up to 1600 mcg twice daily.
Potential Side Effects:
- Headache, jaw pain, nausea, diarrhea, muscle pain, and flushing.
- Side effects generally subside over time, and dose adjustments can alleviate persistent symptoms.
Important Warnings & Precautions:
- Not suitable for individuals with severe liver impairment.
- Pregnancy & Breastfeeding: Should be avoided unless essential.
- Monitoring: Regular cardiovascular and liver function assessments are recommended.
Why Choose Uptravi 400 mcg?
Uptravi represents a cutting-edge treatment option for pulmonary arterial hypertension by combining the effectiveness of prostacyclin receptor activation with the convenience of an oral tablet. It reduces the burden of invasive treatments while delivering clinically proven benefits, making it a preferred choice among specialists and patients alike.
This dosage strength, 400 mcg, is frequently used during the titration phase or as a maintenance dose, providing flexible and individualized treatment plans tailored to the patient’s specific needs.
Storage Guidelines:
- Store at room temperature (below 30°C).
- Keep the tablets in their original packaging to protect from moisture.
- Keep out of reach of children.
Manufacturer & Origin:
- Brand: Uptravi
- Manufacturer: Janssen Pharmaceuticals
- Country of Origin: Europe
Order Uptravi 400 mcg Film-Coated Tablets Online:
We supply original Uptravi 400 mcg tablets sourced directly from authorized distributors. Our streamlined process ensures fast, secure delivery worldwide. Optimize your PAH treatment plan with genuine Selexipag Uptravi 400 mcg—order now for trusted quality and support.
Değerlendirmeler
Henüz değerlendirme yapılmadı.